drugset / Trial / NCT00876447

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

NCT00876447 ↗

Phase 3 Completed 397 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis. This is a follow-up study to two Allergan sponsored studies (NCT00311376 and NCT00461292).

Timeline

Start
2009-01-01
Primary completion
2013-06-12
Completion
2013-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 200 unknown —
Subject Botulinum toxin type A Protein / enzyme biologic 300 unknown —

Indications